Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Lenvatinib + Cadonilimab for Unresectable Hepatocellular Carcinoma
NCT06187961Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Dec 2023
- Primary completion
- Sep 2026
- Modality
- Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital. Started Dec 2023; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06187961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06187961.